[ET Net News Agency, 20 September 2021] Morgan Stanley lowered its target price for
Hepalink (09989) to HK$14.3 from HK$15.1 and maintained its "overweight" rating.
The research house said it cuts its EPS estimates by 8% for 2021, 6% for 2022, and 4% in
2023, and also reduce its forecasts over 2024-2030, following 1H21 earnings. (RC)